UBIC Announces Japan Agency for Medical Research and Development Adopted An R&D Initiative Involving UBIC MEDICAL

UBIC, Inc. UBIC (TSE:2158) ("UBIC" or "the Company"), a leading provider of AI-based, big data analysis services, and UBIC MEDICAL, Inc., a wholly-owned subsidiary of UBIC that provides AI-based, medical data analysis services, announced today that a research and development initiative in which UBIC MEDICAL is involved as an implementing organization has been adopted by the Japan Agency for Medical Research and Development (AMED) as a commissioned project for fiscal 2015. UBIC MEDICAL has been promoting the initiative with Keio University School of Medicine's Research and Development Director and its assistant Professor of Psychiatry, Taishiro Kishimoto. Further details regarding the AMED project, the adopted R&D initiative and the implementing organizations are as follows: AMED Project Name: Research and Development Project Concerning Medical Equipment and Systems to Realize Future Medical Care — "ICT-Based Diagnosis-Assisting Technology Research and Development Project". R&D Initiative: Development of devices that quantify facial expressions, voices and everyday life activities, and that deliver an objective assessment of neurologic manifestations in real time Implementing Organizations: Keio University, Advanced Media, Inc., UBIC MEDICAL, Inc., System Friend, Inc., Semco Techno Co., Ltd., Softbank Corp., and Microsoft Japan Co., Ltd. UBIC MEDICAL contributes to the realization of a healthy and comfortable future by helping all people receive the best possible medical care services through the provision of data analysis systems and services to medical professionals based on its AI technology, which incorporates tacit human knowledge and the outstanding analysis capability of medical data analysis experts to predict behavior.